United States Antimony

Phase A — Understand the business

Lens 1 · Company Overview

United States Antimony Corporation (USAC/"US Antimony") is, in plain terms, the only operating, vertically-integrated, permitted antimony smelter in the United States, bolted to a small zeolite mining business and a precious-metals toll-processing sideline — now being repriced by the market as the designated domestic champion in a US-vs-China critical-minerals standoff.

The real business, stripped to its economics:

• Antimony segment (~90% of revenue, ~$35.4M in FY2025): processes antimony ore (historically bought from a single Canadian supplier, plus new international suppliers in 2025) into three finished products — antimony trioxide (~83% Sb, flame retardants), antimony metal ingots (~99.65% Sb, batteries/bearings/ordnance), and antimony trisulfide (~71.4% Sb, ammunition primer). Smelting at Thompson Falls, Montana (Burns Mining District) plus two facilities in Coahuila, Mexico (USAMSA subsidiary — "the largest operating antimony smelter in Mexico"). The Montana ore also carries gold/silver, which USAC recovers and generally sells back to the ore supplier — that is "substantially all" of precious-metals sales.
• Zeolite segment (~9% of revenue, $3.4M in FY2025): Bear River Zeolite (BRZ), Preston, Idaho — water filtration, animal feed, environmental cleanup. The only segment with an SK-1300 technical report (July 2025). Small but turned gross-profit-positive in 2025.

Contract structure — the entire thesis. Two five-year contracts secured in 2025 transform the demand picture on paper:

1. DLA IDIQ contract (Sept 2025): sole-source, five-year, Indefinite-Delivery/Indefinite-Quantity contract with the US Defense Logistics Agency Strategic Materials for the National Defense Stockpile. Max value $248M for 99.65% antimony metal ingots through Sept 2030. Pricing set per order. Orders of ~$12M received Sept 2025 + Jan 2026 — but zero revenue recognized under it in FY2025.
2. Industrial trioxide contract (Nov 2025): five-year sales agreement, monthly delivery schedule through Dec 2026, semiannual market-based price resets thereafter.

Customer concentration is extreme: the top three customers were 80% of consolidated revenue in 2025 (Customer A $12.9M, B $9.3M, C $9.2M). Domicile reincorporated Montana→Texas (Aug 2025), HQ now Dallas; uplisted to the NYSE March 11, 2026 from NYSE American.

Plain read: this is a sub-scale industrial processor (~$39M total revenue, 100 employees) that has been handed a strategic-monopoly narrative by geopolitics. The investable question is whether the federal-ramp revenue actually shows up — none of it had as of Q1 2026.

Lens 2 · Supply Chain

Map of the chain, every named stakeholder USAC actually discloses:

Upstream (ore in):

• Single Canadian ore supplier — historically "the majority" of Montana feedstock; the ore carries antimony + gold + silver; the supplier buys the recovered precious metals back. Renewed for CY2026. This is the #1 single-source chokepoint — USAC explicitly flags that a decrease/cost increase from this one supplier "could have a material adverse effect".
• New international suppliers (2025) — to the Madero, Mexico facility; "majority of ore received... was of lower quality" early, improving later. Deliberate diversification to cut single-source dependence.
• International hydromet supplier (Oct 2025) — 36-month supply agreement; USAC extended a ~$2.5M promissory note (10% cap) secured by the borrower's assets + personal guarantee to fund their concentrate/equipment purchases. Repayment from March 2026; balance due Dec 2026. (Vendor financing of your own supply chain — see Lens 10.).
• Own mining (new, 2025): Stibnite Hill property (adjacent to Thompson Falls) produced ~840 tons of antimony-bearing material in a 2025 bulk-sampling program — no established reserves/resources; seasonal. Plus Radersburg, MT flotation/concentration facility acquired Jan 2026 for $4.8M; Fostung tungsten claims (Sudbury, Ontario, $5.0M); Alaska (Fairbanks + Koyukuk) and southeastern-US exploration rights. None revenue-producing yet.

Midstream (the company): Thompson Falls smelter (being expanded to "more than triple" capacity, ~$17.1M construction-in-progress, partly DPA-funded) + USAMSA Mexico smelters + the planned Americas Gold & Silver JV hydrometallurgical refinery (Feb 2026; 51% Americas / 49% UAMY; UAMY managing member; UAMY funds 49% of capex; JV depends on Americas-supplied ore).

Downstream (product out):

• US Government / DLA — the new anchor buyer (National Defense Stockpile).
• One industrial trioxide customer (5-yr contract).
• The Canadian ore supplier — buys gold/silver back (precious-metals "sales" are really a closed loop).
• End-markets: flame retardants (plastics/textiles), lead-acid batteries, ammunition primer/ordnance, bearings.

Chokepoints: (1) one Canadian ore supplier; (2) one BRZ zeolite lease (Zeolite LLC, through Dec 2034); (3) reliance on the DLA actually placing orders; (4) the Americas JV's dependence on a partner's mine. This is a chain with single points of failure at nearly every node.

Lens 3 · Competitive Advantages (moats)

The moat is regulatory/strategic, not economic — and that distinction is the whole bear case.

What is genuinely durable:

• Sole US permitted, vertically-integrated antimony smelter. Permitting a US smelter is slow and politically fraught; this is a real barrier to a new domestic entrant.
• Incumbency with the US Government — a sole-source DLA IDIQ + a $27M DPA Title III award (see Lens 5) embed USAC in the defense supply chain. In a "critical minerals independence" policy regime, being the only domestic processor is a privileged position.
• Largest antimony smelter in Mexico (USAMSA) — adds non-China processing capacity in the Western hemisphere.

What is NOT a moat:

• No cost advantage. Average cost/lb of antimony rose 254% to $18.21 in 2025; the business is a price-taker tied to the Rotterdam market. When the antimony price falls, the spread compresses fast (already visible in Q1 2026).
• No proprietary ore. USAC owns no producing mine; it processes other people's ore. Reserves are "n/a — none established" outside the zeolite TRS.
• Bargaining power is weak both ways: it depends on one Canadian ore supplier (supplier power high) and 3 customers = 80% of revenue (customer power high). The only counterparty it has leverage over is a tiny international supplier it had to lend money to.
• Estimated market share: ~4% of domestic antimony trioxide, <1% international. This is a minnow in global terms; the "champion" status is about location, not scale.

Net: the moat is "the US needs a domestic processor and we're the only one with the permits." That is real and policy-durable — but it is a moat around a structurally low-return commodity-processing business, and it does not protect margins.

Lens 4 · Segments

Revenue and gross profit by segment, FY2025 vs FY2024, all ``:

Antimony operating metrics tell the real story — this was a price event, not a volume event:

• Pounds sold actually fell 3% (1,408,513 → 1,459,557 lbs) on workforce constraints + furnace refurbishment.
• Average sales price/lb +230% ($7.61 → $25.12), tracking the Rotterdam spot (avg $10.44 → $23.88).
• Average cost/lb +254% ($5.15 → $18.21) — costs rose faster than price, but a wider absolute spread still lifted gross profit/lb from $2.46 to $6.91.

By geography: all sales are to customers "primarily in the United States and Canada". Segment assets: antimony $137.0M, zeolite $5.7M, "all other" (mining claims, AK/Canada, apartment complex) $11.2M.

Trend & cause: The 2025 surge is almost entirely the antimony-price spike following China's export controls. It is decelerating already (price moderated in H2 2025; Q1 2026 gross profit -58% YoY). The segment mix is overwhelmingly one commodity at one point in a price cycle — there is no diversified earnings base underneath the headline growth.

---

Phase B — Measure performance

Lens 5 · Earnings Result (latest print — Q1 2026, filed 2026-05-14)

The most important read in this dossier. Q1 2026 was a sharp miss and a swing to a large loss:

Decomposition (this matters — the loss is two separate problems):

1. Operating loss of $7.5M — driven by an explosive $5.9M salaries-and-benefits line (vs $1.0M; heavily share-based-comp-loaded) and gross margin halving as higher-cost ore inventory flowed through COGS faster than ASP rose. Management framed the cost build as deliberate — "higher labor, factory, and import freight costs... needed to get the talent, factory, and inventory required for the expected ramp-up".
2. $4.1M non-cash mark-to-market loss on the Larvotto stake (AUD-denominated, marked each quarter).

Antimony Q1: revenue −6%, but ASP actually rose to $19.92/lb from $16.34 — the gross-margin compression was cost/spread- and volume-timing-driven, not a price collapse. Crucially, Q1 2026 recognized $0 of DLA contract revenue and $0 from in-house Montana ore — both are entirely H2-weighted.

Balance-sheet flag — cash burned hard: cash fell from $30.5M (Dec 31, 2025) to $3.2M (Mar 31, 2026), with $20.5M of Treasury strips as backup liquidity (~$23.7M total). The DPA award is milestone-based: $16.2M obligated, $12.8M achieved/received as a grant receivable against Thompson Falls CIP. Management has applied for $274M more in government funding (no assurance).

Market reaction: stock fell ~4% on the print; a separate Simply Wall St note framed it as "down 16.4% after defense-funded expansion push amid weak Q1" over the surrounding window. Guidance reaffirmed at $125M gross revenue for 2026 ($75–95M from federal ingot sales). Against $6.8M booked in Q1, that implies ~$118M across Q2–Q4 — a near-vertical ramp.

Unusual vs the company's own history: the salaries/SBC line and the equity-mark volatility are both new and large; the company has now missed at Q3 2025 and Q1 2026 against the federal-ramp narrative.

Lens 6 · Earnings Calls (sentiment trend)

No transcripts on disk (transcripts/ empty) — this lens is ``.

Tone trajectory across the last ~3 calls (Q3 2025 → Q1 2026):

• Q3 2025 (Nov): "misses forecasts, stock dips" — but the narrative pivoted hard to the just-signed $245M DLA deal as the forward story.
• Q4/FY2025 (March 2026): uplisting + DPA award + Americas JV + Radersburg + the Larvotto takeover bid — a blitz of strategic announcements layered over weak operating numbers.
• Q1 2026 (May): management leaned entirely on (a) reaffirmed $125M guidance, (b) "record zeolite sales," (c) the cost build being "investing ahead of the ramp".

Recurring phrases: "ramp," "federal government," "vertically integrated," "critical minerals," "strategic." What's conspicuously downplayed: the actual cadence of DLA orders converting to recognized revenue, and the dilution funding it all. The pattern is classic momentum-management — every disappointing print is immediately re-anchored to a bigger future number and a fresh strategic deal. Sentiment is promotional-optimistic and has stayed there regardless of results.

Lens 7 · Comps

Antimony-exposed equities. Multiples for UAMY are meaningful only with heavy caveats — it is loss-making (no meaningful P/E or EV/EBIT), and EV/Sales is on a depressed ~$39M trailing base that management says triples this year. Provenance: market caps ``; "n/a" where a clean multiple was not retrievable.

The comp that matters: UAMY vs PPTA. Perpetua is ~3x UAMY's market cap, has a $2.9B EXIM-backed, permitted, 15-year mine plan with far more contained antimony — but no production yet and a gold-primary economic engine. UAMY has actual (if tiny, loss-making) US smelting today and the sole-source DLA contract. The market is paying ~$1.1B for ~$39M of trailing revenue and a $125M promise. On any normalized basis UAMY screens expensive; the bull defense is entirely "strategic scarcity + federal demand," not multiples.

Lens 8 · Stock-Price Catalysts (last 5 years)

UAMY is one of the most volatile names on the tape — a pure critical-minerals/defense momentum vehicle.

Moves >5% and what drove them:

• 2024 China antimony export controls / ban → antimony price from ~$10/lb to a Rotterdam peak of $59,750/t (July 2025) → the entire bull thesis ignites.
• Sept 2025 — $245M DLA contract announced → the defining catalyst; stock ran from ~$1.77 (start 2025) toward its $19.71 all-time high (mid-Oct 2025).
• Oct 2025 — $470M Larvotto takeover bid → ambition signal; also the start of the AUD mark-to-market exposure.
• Late 2025 — antimony price moderates off the July peak + Larvotto rejects the bid → stock collapses from ~$19.71 to mid-single digits.
• March 2026 — NYSE uplisting + $27M DPA award → institutional-base catalyst; partial recovery to ~$7.62 now.
• Nov 2025 / May 2026 earnings misses (Q3'25, Q1'26) → −4% to −16% drawdowns.

What the pattern reveals: the market reacts to policy and contract headlines (China controls, DLA, DPA, uplisting), not to quarterly fundamentals — earnings prints are an afterthought to the geopolitical narrative. The stock is effectively a levered call option on (a) the antimony price and (b) US critical-minerals policy, with ~18-19% short interest (26.5M shares) adding squeeze fuel in both directions. Current ~$7.62 sits well off the $19.71 high but ~4x the early-2025 base — the re-rating is partly digested, not fully unwound.

---

Phase C — Judge people & books

Lens 9 · Management

Gary C. Evans — Chairman & CEO (since Dec 2024; Chairman since July 2023). This is the most important judgment call in the dossier, because the equity trades on his narrative.

1. Track record — genuinely impressive and genuinely cautionary. Serial energy entrepreneur. Founded the original Magnum Hunter Resources, sold to Cimarex for ~$2.2B in 2005 — a real, large, value-creating exit. Built Eureka Hunter pipeline, GreenHunter. Claims to have raised >$8B on Wall Street over his career. Long-time Novavax director (NVAX hit >$20B in the pandemic). So: a proven capital-raiser and deal-maker.
2. The omission that matters. The 10-K bio describes the second Magnum Hunter Resources (Appalachian/Eagle Ford) as "now part of Southwestern Energy" — but omits that that company filed Chapter 11 in Dec 2015 and Evans was forced out as CEO when it emerged from bankruptcy in May 2016; common equity was wiped out. More damning: weeks before the filing, the company posted a presentation valuing assets at $8.77–$13.77/share while the stock traded under $1. That is a documented instance of promotional valuation behavior into a collapse — and it is the precise risk pattern an investor must price for UAMY's current promotional cadence.
3. Tenure & skin in the game — thin. Evans owns ~3,629,565 shares = 2.5%; all directors & officers as a group = 5.7%. He holds cheap legacy options (500,000 @ $0.22 strike, expiring 2027) that are deeply in the money — alignment is more "option upside" than "founder capital at risk." Largest holders are passive index funds (State Street 5.3%, Vanguard 5.2%, Creative Planning 5.2%) — no strategic or activist anchor; ~1,800 record holders, a retail-dominated float.
4. Capital-allocation history on this watch — aggressive and mixed. In 2025–26 he: raised ~$110M (heavily dilutive — see Lens 10); bought a 10% Larvotto stake for $37.2M then launched a $470M all-stock takeover that Larvotto's board unanimously rejected as undervaluing them, leaving USAC holding an illiquid, loss-generating AUD position; entered a 49%-minority JV where it carries managing-member liability; and acquired a scattershot of early-stage claims (AK, Ontario, SE-US). This is a roll-up-and-promote playbook, not disciplined capital stewardship.
5. Founder vs professional manager: archetype is promotional founder/dealmaker — exactly the profile that can mint a multibagger in a commodity up-cycle and exactly the profile that left Magnum Hunter equity holders with nothing. The board adds real heavyweights — Gen. Jack Keane (national-security authority — materially useful for the DLA/DPA relationship), Joseph Carrabba (ex-CEO Cleveland-Cliffs), Jon Marinelli (energy banker) — which lends credibility, but 5 of 7 are independent and ownership is low.

CFO Richard Isaak (ex-EY CPA, since July 2023) is appropriately credentialed — relevant given the controls issue below.

Lens 10 · Forensic Red Flags

Acting as a forensic analyst. Multiple genuine flags; none are fraud signals, but together they describe a company whose accounting complexity has outrun its infrastructure.

Most serious — material weakness in disclosure controls. In the Q1 2026 10-Q, the PEO and PFO concluded the Company's disclosure controls and procedures were NOT effective, attributing it to "the small size of the Company's accounting staff." Remediation (SOX hires, new accounting software, a third-party firm) is "expected to be completed in 2026". For a company simultaneously running a government contract, a cross-border (Mexico/Canada) footprint, a JV, and AUD-denominated mark-to-market investments, ineffective controls is a real risk to reported-number reliability.

Earnings quality / cash-vs-earnings divergence:

• Operating cash flow was −$9.7M in FY2025 despite $9.9M gross profit — a $12.2M inventory build (antimony stockpiled at high cost) drove the gap. Inventory grew from $1.2M to $12.5M; ~$4M of it wasn't even processed until Q1 2026.
• Share-based compensation flatters nothing and costs plenty: SBC was $7.1M in FY2025 (vs $0.6M in FY2024) — larger than the entire $4.3M net loss; in Q1 2026 the $5.9M salaries-and-benefits line is heavily SBC. This is a real economic cost to shareholders via dilution, parked in a "non-cash" framing on the calls.
• Larvotto fair-value volatility: the AUD equity stake injects multi-million-dollar non-operating swings into net income every quarter ($3.3M gain in FY2025, then a $4.1M loss in Q1 2026) — earnings are now partly a proxy for an Australian small-cap's share price.
• Vendor financing of the supply chain: the $2.5M secured promissory note to an international ore supplier blends "customer/supplier" and "lender" relationships — recovery depends on a foreign borrower's solvency and enforceability.
• IVA (Mexican VAT) receivable reserves: a $1.3M IVA refund-reserve charge in 2025 signals difficulty collecting VAT refunds in Mexico — a recurring soft spot for the USAMSA operations.

Related-party: minor — the Company hired Angel Beltran, son-in-law of CEO Gary Evans, in antimony operations (March 2026), at compensation "consistent with" peers. Small, disclosed, but a governance texture worth noting alongside the low insider ownership and promotional history.

Insider selling signal: Director Michael McManus adopted a Rule 10b5-1 plan (March 2026) to sell up to 100,000 shares between June–Dec 2026. Routine and pre-planned, but a director monetizing into the rally.

Auditor: Assure CPA, LLC (Spokane, WA; PCAOB ID 444), auditor since 1998. Clean opinion, no critical audit matters, no going-concern qualification. Note the tension: a small regional auditor signing off on a company that itself admits its internal controls are not effective — not disqualifying, but the kind of pairing short-sellers probe.

Regulatory findings (required sub-section):

• SEC Litigation Releases: None. No LR naming United States Antimony in the search period (2021-06-17 → 2026-06-17).
• SEC AAERs: None.
• Item 3 Legal Proceedings (FY2025 10-K) and Part II Item 1 (Q1 2026 10-Q): "United States Antimony Corporation is not a party to any material legal proceedings." No director/officer/5%-holder adverse interest.
• Non-SEC enforcement (web): No material FTC/DOJ/FDA/CFPB enforcement actions, consent decrees, or penalties against the company surfaced in searches.
• Conclusion: No material regulatory or legal findings — verified via SEC EDGAR EFTS (LR, AAER), web search, and 10-K Item 3 / 10-Q Part II Item 1 as of 2026-06-18. The red flags here are accounting-infrastructure and capital-allocation flags, not enforcement or litigation flags.

---

Phase D — Project & stress-test

Lens 11 · Forward Projection

USAC's earnings are not yet a stable base to forecast — the entire 2026 thesis hinges on a binary: does the DLA federal ramp convert to recognized revenue in H2 2026 or not? I model EPS for FY2026–FY2028. Every input labeled; output ``.

Anchor actuals: FY2025 revenue $39.3M, net loss $4.3M, EPS −$0.04; ~140M shares (123.6M wtd avg FY2025; 141.6M Q1 2026).

FY2026 (base): Management guides $125M gross revenue ($75–95M federal). Assume $95M actual (a 24% haircut to guidance, since Q1 booked $6.8M and zero DLA, requiring ~$88M in Q2–Q4 — aggressive but with ~$85M of stated DLA orders behind it). At a normalized ~22–25% gross margin on the ramp (federal ingot pricing should be steadier than spot trioxide), gross profit ~$22M; but opex is running ~$30M annualized (SBC-heavy) plus Larvotto mark volatility. Base FY2026 EPS ~ −$0.10 to −$0.20. The company likely stays loss-making in 2026 even if revenue triples, because opex and SBC scale with the build-out.

• Bull FY2026: $125M revenue hit, opex discipline, Larvotto mark neutral-to-positive → roughly breakeven to +$0.05 EPS.
• Bear FY2026: DLA orders slip into 2027, revenue ~$55–65M, continued cost build, Larvotto markdown → EPS −$0.25 to −$0.40; cash (only $3.2M + $20.5M Treasuries) forces another dilutive raise.

FY2027: if the DLA contract runs at scale (toward the $248M/5yr ≈ ~$50M/yr cadence) plus the industrial contract plus Americas JV first contribution → revenue $130–170M; first plausible GAAP profitability, base EPS ~$0.10–$0.30, heavily dependent on the antimony price holding above ~$25/lb.

FY2028: full smelter-expansion (3x capacity) utilized + JV ramped → revenue $160–220M; base EPS ~$0.25–$0.50. This is the "it worked" scenario that today's ~$1.1B cap is discounting.

The honest summary: at ~$7.62 / ~$1.1B cap, the market is paying ~25–40x a 2028 best-case EPS that requires (a) the antimony price to stay elevated, (b) the DLA to actually order ~$50M/yr, and (c) the cost structure to operate-leverage. Any one of those failing and the multiple has no support. n/a — no reliable sell-side EPS consensus exists beyond H.C. Wainwright's single-analyst model; the $11–$11.75 price targets are PT-on-narrative, not a consensus EPS build.

Per --watchlist rules, no Brier forecast logged (forecast.ts create skipped in breadth mode).

Lens 12 · Bull vs Bear

Bull case (narrative). Antimony is a genuine, structural, weaponized supply chokepoint — China dominates production and has used export controls as leverage. The US must onshore antimony processing, and UAMY is the only permitted, vertically-integrated domestic smelter — a position you cannot replicate quickly. The $248M DLA sole-source contract + $27M DPA award are the US Government writing checks to make this happen; $125M of 2026 revenue with $75–95M federal is the first proof. Capacity is tripling, fully/partly government-funded. Add the Americas JV refinery, the Radersburg flotation plant, the Larvotto/Hillgrove optionality, and a board with Gen. Jack Keane wired into the defense establishment. The balance sheet has zero meaningful debt and ~$140M of equity. If the ramp converts, this is a $200M-revenue, profitable, strategically-protected national champion and today's cap looks early. Secular tailwind (critical-minerals reshoring) + earnings surprise potential (any DLA order beat) + scarcity = the bull's trifecta.

Bear case (2–3 permanent-impairment risks).

1. The revenue is a promise, not a fact — and the promiser has wiped out equity before. Zero DLA revenue in Q1; the entire $125M guide is back-end-loaded into H2 2026 under a CEO who valued Magnum Hunter at $8–14/share weeks before it went to $0. If the ramp slips (it already slipped at Q3'25 and Q1'26), the stock has no fundamental floor — it's priced for execution that hasn't happened.
2. It's a price-taking commodity processor with no cost moat, into a softening antimony price. Rotterdam peaked at $59,750/t (July 2025) and is falling; China suspended its US export ban until Nov 27, 2026, and the 2026 market is expected "adequately supplied". The supply shock that made the thesis is partially unwinding. Cost/lb already rose faster than price; Q1 gross margin halved.
3. Dilution + cash burn + ineffective controls. Shares grew to ~141M; the company funded itself with ~$110M of equity issuance and burned cash to $3.2M in one quarter. With controls self-assessed as "not effective," the reported numbers carry elevated risk, and another dilutive raise looks probable if the ramp is late.

Pre-mortem (18 months out, thesis broke): It's late 2027. DLA orders came in lumpy and well below the $50M/yr implied pace; the antimony price normalized to the low-$20s/lb as Southeast-Asian and Larvotto/Hillgrove supply arrived; UAMY's gross margins stayed thin because it never controlled ore; the Larvotto stake was marked down further; the company did two more dilutive raises; the stock round-tripped to $3. The "national champion" was real but the economics of being a sub-scale processor never justified a $1B+ cap.

Are multiples too high? Yes, on any normalized basis — ~28x trailing EV/Sales, no earnings. The only defense is strategic-scarcity + federal-demand optionality, which is a story multiple, not a value multiple.

Contrarian view (what the market refuses to see): The bulls treat the DLA contract's $248M max value as a revenue forecast; it is a ceiling on a sole-source IDIQ with pricing set per order — the government is obligated to almost nothing. And the bears treat the whole thing as a pump; but the strategic position (sole US smelter, real DPA money, real defense board) is genuinely durable and would matter enormously in a hot US-China critical-minerals decoupling. The truth the market is mispricing in both directions: this is a policy option, not an operating business — it should be sized like a call option (small, asymmetric, time-decaying), not owned like a compounder.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull case. The ~18-19% short interest says the smart-money skeptic trade is already on.

• Where revenue is concentrated: 80% from 3 customers, and the future 60-75% from a single counterparty (the US Government) under a contract with no minimum purchase obligation. If the DLA orders slowly, the model breaks — and there is zero contractual recourse.
• Why the moat is weaker than bulls think: "Only US smelter" is a barrier to new domestic entrants, not to the global antimony market. Perpetua (Stibnite) is coming with a vastly larger, EXIM-financed asset; Larvotto/Hillgrove production starts Q2 2026; Trigg has a top-3 Western resource. UAMY has no ore of its own and no cost advantage — its "moat" is a permit, not a margin.
• Most dangerous competitor bulls underestimate: Perpetua (PPTA) — once Stibnite produces, the US has a domestic antimony mine + mill with gold by-product economics that can subsidize the antimony, structurally undercutting a pure processor. And the simplest competitor of all: China lifting export controls (already suspended to Nov 2026), which collapses the scarcity premium.
• Worst capital-allocation moves: the $470M all-stock Larvotto bid that got rejected (now a stranded, loss-marking 10% AUD stake); funding the company with ~$110M of dilution; lending $2.5M to a supplier; a scattershot of pre-resource claim purchases. This is empire-building into a price spike.
• Assumptions that must hold for today's price: antimony stays >$25/lb; DLA orders ~$50M/yr; opex operate-leverages; no further dilution; controls get fixed; Larvotto doesn't mark down further. That's six things, and two already broke in Q1.
• If growth disappoints 20–30%: revenue ~$85–95M instead of $125M → still loss-making → another raise → the narrative multiple compresses violently (the stock has already shown it can go $19.71 → mid-single-digits in weeks).
• Single scenario that permanently impairs: China fully and durably normalizes antimony exports + Perpetua/Larvotto supply arrives, antimony settles to the high-teens/low-$20s, and the DLA stockpile fills slowly. UAMY reverts to what it was for decades — a marginally-profitable micro-cap processor — and the $1B cap is revealed as a policy-cycle artifact. Plausibility: moderate-to-high over 2–3 years.

Lens 14 · Management Questions (ordered by information value)

1. Of the ~$85M in stated 2026 DLA orders, how much is firm/funded versus indicative, and what is the recognized-revenue schedule by quarter — what specifically converts the $6.8M Q1 into the implied ~$118M for Q2–Q4?
2. The DLA contract has a $248M ceiling but no minimum purchase obligation — what is the realistic annual order cadence the DLA has signaled, and what happens to guidance if 2026 orders come in at half the run-rate?
3. Cash fell to $3.2M at March 31. What is the bridge to year-end, and at what revenue shortfall do you need another equity raise — and how do you weigh further dilution against the ~141M shares already out?
4. Your own disclosure controls were assessed "not effective." Precisely what is unremediated today, what is the completion date, and who owns it — given you run a government contract, a JV, and foreign subsidiaries?
5. You bid $470M for Larvotto and were rejected. What is the plan for the stranded ~10% AUD stake — hold, sell, re-bid, or write down — and what did that episode teach you about capital allocation?
6. Gross margin halved in Q1 on cost-per-pound outrunning price. At what antimony price does the antimony segment stop being gross-margin-positive, and how much of your 2026 plan assumes a price above today's level?
7. China suspended its US antimony export ban to Nov 2026 and 2026 supply is expected "adequate." How does your thesis survive a normalized antimony price in the low-$20s/lb?
8. You've applied for $274M of additional government funding. What is the probability-weighted timeline, and how much of the capex plan is contingent on money you don't yet have?
9. On the Americas JV: you're a 49% minority funding 49% of capex but carrying managing-member liability and depending on Americas' ore. Why is that the right risk/return versus owning your own processing outright?
10. SBC was $7.1M in 2025 — larger than your net loss — and dominates the Q1 salaries line. What is the multi-year dilution path from equity comp, and how do you defend it given 5.7% insider ownership?
11. You hold no proven/probable reserves outside the zeolite TRS. What is the timeline and capex to convert Stibnite Hill / Alaska / Fostung into actual reserves, and what do you do for ore if your single Canadian supplier reduces volume?
12. CEO bio: how do you address investor concern about the Magnum Hunter Chapter 11 and the pre-bankruptcy valuation presentation, and what is different about your capital discipline here?
13. What is the steady-state, mid-cycle gross margin of this business once the federal ramp is mature — i.e., what are normalized earnings, not peak-price earnings?
14. The $2.5M supplier note and the IVA receivable reserves both signal collection/credit friction. What is your exposure to foreign-counterparty and Mexican-VAT recovery risk?
15. If antimony reverts to its pre-2024 ~$10/lb world in 2027–28, what does this company look like, and what is the downside scenario you'd give a long-term shareholder?

---